SCHEMBL4343203

SCHEMBL4343203

CN(C)CCNC(=O)c1cc2c(-c3cccc(F)c3)n[nH]c2cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT1 P04628 3/20 0.52
DYRK1A Q13627 3/20 0.52
MAPK8 P45983 2/20 0.50
MAPK10 P53779 2/20 0.50
MAPK14 Q16539 2/20 0.50
MAPK1 P28482 2/20 0.49
RAD52 P43351 3/20 0.44
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CDC7 O00311 1/20 0.43
CDK19 Q9BWU1 1/20 0.43
UHRF1 Q96T88 1/20 0.43
MAP2K4 P45985 1/20 0.43
ACKR3 P25106 1/20 0.42
CSNK1D P48730 1/20 0.42
CHEK1 O14757 1/20 0.40
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
NTRK1 P04629 1/20 0.40
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4332627 0.91 MAPK8 (0.49) WNT1DYRK1AMAPK8MAPK10MAPK14
SCHEMBL4334482 0.88 MAP4K4 (0.51) DYRK1AMAPK8MAPK1MAP2K4CDK4
SCHEMBL4340999 0.83 WNT1 (0.51) WNT1DYRK1AMAPK8MAPK10MAPK14
SCHEMBL2861793 0.79 DYRK1A (0.53) WNT1DYRK1AMAPK8MAP2K4
SCHEMBL4334601 0.79 MAP4K4 (0.50) DYRK1AMAPK8MAPK1MAP2K4CDK4
SCHEMBL27558524 0.79 MAP2K4 (0.54) DYRK1AMAPK1MAP2K4CSNK1DNTRK1
SCHEMBL4332113 0.78 KDM4E (0.52) WNT1DYRK1AMAPK1ALDH1A1SMN1; SMN2
SCHEMBL4328143 0.78 HPGD (0.53) MAPK8MAPK1ALDH1A1SMN1; SMN2
SCHEMBL2862186 0.78 SMN1; SMN2 (0.56) DYRK1AMAPK8MAPK1SMN1; SMN2CSNK1D
SCHEMBL2857674 0.78 MAP2K4 (0.60) MAPK1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 WNT1 77/4885DYRK1A 1216/4885MAPK8 10/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 WNT1 77/4885DYRK1A 1216/4885MAPK8 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.